ConMed
CNMD
44.23
-0.25
-0.56%
ConMed
US · CNMD
#3018 by market cap
Listed 1970
44.23
-0.25
-0.56%
Live - 5344 symbols - heartbeat 11s ago
· 2026-10-08 09:04
Pre-market
43.91
-0.72%
After-hours
44.23
0.00%
Overnight
44.24
+0.02%
- Market cap
- 1.32B
- P/E (TTM)i
- 23.91
- P/Bi
- 1.27
- EPSi
- 1.51
- Div yieldi
- 0.45%
- 52W posi
- 58%
Reader sentiment
Are you bullish or bearish on CNMD?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.1 percentage points.
Institutional ownership
- Held by institutions
- 114.33% -0.14pp
- Institutions
- 301 -3
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund101.42%
Hedge Fund6.92%
Public Company3.30%
Government Pension Fund1.22%
Private Company1.14%
Individual/Insider0.89%
Insurance Company0.15%
Top holders as of 2026-06-30
BlackRock
16.10% · 4.82M sh
EARNEST Partners, LLC
8.36% · 2.51M sh
Vanguard Portfolio Management, LLC
7.31% · 2.19M sh
Fuller & Thaler Asset Management, Inc.
5.27% · 1.58M sh
Vanguard Capital Management, LLC
5.20% · 1.56M sh
State Street Global Advisors
4.73% · 1.42M sh
Dimensional Fund Advisors
4.40% · 1.32M sh
Managed Account Advisors LLC
3.78% · 1.13M sh
SEI Investments Company
3.30% · 988.15K sh
Invenomic Capital Management LP
2.81% · 842.16K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 37 buys · 7 sells
| Name | Role | Stake |
|---|---|---|
| Curt Hartman | Chairperson & CEO | 0.31% |
| Heather Cohen | Executive VP and Chief Human Resources & Legal Officer | 0.14% |
| John Workman | Independent Director | 0.07% |
| David Bronson | Independent Director | 0.06% |
| Charles Farkas | Independent Director | 0.05% |
| Stephan Epinette | -- | 0.05% |
| Martha Aronson | Lead Independent Director | 0.05% |
| Patrick Beyer | President of International & Global Orthopedics | 0.04% |
| Brian Concannon | Independent Director | 0.03% |
| Barbara Schwarzentraub | Independent Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-07 | Kim Kelderman | Director | Derivative Exercise and Retained | +500 | -- |
| 2026-07-14 | John Gallagher | Executive VP, CFO and Principal Financial & Accounting Officer | Other Derivative Acquisition | +30,536 | $42.79 |
| 2026-07-14 | John Gallagher | Executive VP, CFO and Principal Financial & Accounting Officer | Other Derivative Acquisition | +61,929 | -- |
| 2026-07-14 | John Gallagher | Executive VP, CFO and Principal Financial & Accounting Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-06-30 | Jeffrey Mirviss | Director | Other Derivative Acquisition | +5,603 | -- |
| 2026-06-30 | Jeffrey Mirviss | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-06-30 | Celine Martin | Director | Other Derivative Acquisition | +5,603 | -- |
| 2026-06-30 | Celine Martin | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-06-01 | David Bronson | Independent Director | Derivative Exercise and Retained | +668 | -- |
| 2026-06-01 | Laverne Council | Independent Director | Derivative Exercise and Retained | +668 | -- |
| 2026-06-01 | Mark Kaye | Director | Derivative Exercise and Retained | +668 | -- |
| 2026-06-01 | Charles Farkas | Independent Director | Derivative Exercise and Retained | +668 | -- |
| 2026-06-01 | Barbara Schwarzentraub | Independent Director | Derivative Exercise and Retained | +668 | -- |
| 2026-05-31 | David Bronson | Independent Director | Other Derivative Acquisition | +5,772 | -- |
| 2026-05-31 | Kim Kelderman | Director | Other Derivative Acquisition | +5,772 | -- |
| 2026-05-31 | Laverne Council | Independent Director | Other Derivative Acquisition | +5,772 | -- |
| 2026-05-31 | Mark Kaye | Director | Other Derivative Acquisition | +5,772 | -- |
| 2026-05-31 | Charles Farkas | Independent Director | Other Derivative Acquisition | +5,772 | -- |
| 2026-05-31 | Barbara Schwarzentraub | Independent Director | Other Derivative Acquisition | +5,772 | -- |
| 2026-05-31 | Kimberly Lockwood | Interim Corporate Controller | Initial Statement of Beneficial | 0 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:04:27 · For reference only, not investment advice and not tailored to your situation.